12 assets in Astrocytoma, IDH-Mutant, Grade 4

Therapeutic assets addressing Astrocytoma, IDH-Mutant, Grade 4, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Astrocytoma, IDH-Mutant, Grade 4	Andrew P. Groves	P2	B (60)
Safusidenib Astrocytoma, IDH-Mutant, Grade 4	Nuvation Bio Inc.	P3	B (60)
gi-102 Astrocytoma, IDH-Mutant, Grade 4	Mayo Clinic	P2	CCC (53)
Ipilimumab Astrocytoma, IDH-Mutant, Grade 4	National Cancer Institute (NCI)	P2	CCC (53)
Pembrolizumab Astrocytoma, IDH-Mutant, Grade 4	Mayo Clinic	P2	CCC (53)
Eflornithine Astrocytoma, IDH-Mutant, Grade 4	Mayo Clinic	P1/2	CC (47)
Retifanlimab Astrocytoma, IDH-Mutant, Grade 4	Mayo Clinic	P1/2	CC (47)
Allogeneic Adipose-Derived Mesenchymal Stem Cells Astrocytoma, IDH-Mutant, Grade 4	Mayo Clinic	P1	CC (43)
Anti-Il13Ralpha2 Car T-Cells Astrocytoma, IDH-Mutant, Grade 4	City of Hope Medical Center	P1	CC (43)
Azacitidine Astrocytoma, IDH-Mutant, Grade 4	Andrew P. Groves	P1	CC (43)
Fludeoxyglucose Astrocytoma, IDH-Mutant, Grade 4	City of Hope Medical Center	P1	CC (43)
Triapine Astrocytoma, IDH-Mutant, Grade 4	National Cancer Institute (NCI)	P1	CC (43)